Kornimate/medical-research-clean huggingface dataset:
safety and efficacy of carpal stim in treating carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the objective of this study is to assess the efficacy and safety of carpal stim for pain relief in cts subjects.


Eligibility criteria:
inclusion criteria: 1. male or female subjects aged ≥ 20 years old during the recruitment phase 2. clinical diagnosis of cts： 1. diagnosis of cts was confirmed by nerve conduction velocity (ncv) but not limited to ncv 2. symptoms consistent with cts for at least 3 months and the numerical rating scale (nrs) score ≥ 5 during the recruitment phase 3. willing to abstain from any other treatment or therapy for cts throughout the trial except protocol-described medications 4. the subject is willing and able to comply with the procedure and requirements of this trial 5. the participant is able to understand and provide informed consent, and has signed their written informed consent in accordance with irb requirements exclusion criteria: 1. wrist fractures or cysts at the cts affected side 2. wrist surgery within the past 3 months, especially carpal tunnel release surgery at the cts affected side 3. receiving upper limb (including neck) surgery 4. injections of corticosteroids/cortisone into the wrist or hand within the past 3 months 5. with a past medical history of diabetic polyneuropathy 6. with a past medical history of rheumatoid arthritis 7. with a past medical history of epilepsy 8. body mass index (bmi) \> 40 kg/m2 9. participation in any investigational study in the last 2 weeks or current enrollment in any trial. 10. active infection at the stimulator contact site during the recruitment phase 11. pregnant women or diagnosed with postpartum edema in the wrist per investigator's discretion 12. patients with implanted medical devices that are electronic products, such as implantable cardioverter defibrillators, pacemakers, spinal cord stimulation systems, or spinal cord drug infusion pumps
laser treatment for the improvement of scars and scleroderma

Conditions: Scars; Scleroderma

Summary: in this study, the investigators seek to evaluate the effects of a laser treatment on the redistribution/regeneration of collagen on the clinical, microscopic, and molecular profiles of hypertrophic scars and scleroderma.

this study is designed to evaluate the efficacy of laser treatment for the improvement of the clinical appearance of disorders of collagen metabolism, including hypertrophic scars and scleroderma. the investigators will be performing a prospective cohort study. the entire lesion will receive laser treatment only. the investigators plan to have 20 patients (10 patients with hypertrophic scars and 10 patients with scleroderma) complete the study. subjects must be equal to greater than 18 years old, but may be any gender or fitzpatrick skin type. they must have one of the following: at least one extragenital hypertrophic scar, or at least one extragenital area of scleroderma . subjects must not have received any prescription or in-clinic medications or treatments, such as intralesional corticosteroids or excision, on the eligible scars/scleroderma in the previous 3 months. those on anti-inflammatory or immunosuppressive medications will also be excluded.

Eligibility criteria:
inclusion criteria: 1. subject must be able and willing to provide written informed consent and comply with the requirements of the study protocol; 2. in good general health, based on answers provided during the screening visit; 3. subject must be able to read and understand english; 4. any gender and any fitzpatrick skin type; 5. age equal to or greater than 18 years old; 6. subjects in the hypertrophic scar branch must have at least one extragenital hypertrophic scar (defined as abnormal proliferation of scar tissue that forms at the site of cutaneous injury and does not regress and grows beyond the original margins of the scar) large enough to treat for both the control and experimental arm (at least 4cm in length for spit scar treatment) or two similar hypertrophic scars (at least 4cm2 for each); 7. subjects in the scleroderma branch must have eligible extragenital lesions; large enough to treat for both the control and experimental arm or two similar scleroderma areas (at least 4cm2 area for each); exclusion criteria: 1. participation in another investigational drug or device clinical trial in the past 30 days; 2. are pregnant or lactating; 3. use of any prescription or in-clinic medications or treatments, such as intralesional corticosteroids or excision, on the eligible scars/scleroderma in the previous 3 months; 4. history of allergic reaction to topical or local anesthesia; 5. regular intake of high doses of anti-inflammatory drugs (aspirin \>81 mg/day, ibuprofen, corticosteroids, etc.) or immunosuppressive drugs; 6. clinically significant abnormal findings or conditions which might, in the opinion of the investigator, interfere with study evaluations or pose a risk to subject safety during the study.

Keywords: scar scleroderma laser
halo patient registry: ablation of barrett's esophagus

Conditions: Barrett Esophagus

Summary: the halo patient registry is a prospective/retrospective, multi-center patient registry. it provides a framework for treatment and follow-up of patients with barrett's esophagus (non-dysplastic im, lgd and hgd). the primary objective is to provide a tool for participating physician investigators to collect outcomes data related to the use of the halo ablation systems.

summary the halo patient registry provides a framework for treatment and follow-up of patients with barrett's esophagus (non-dysplastic im, lgd and hgd). the primary objective is to provide a tool for participating physician investigators to collect outcomes data related to the use of the halo ablation systems. protocol design: this is a prospective, multi-center patient registry. sites may choose to also retrospectively enroll previously treated patients (after obtaining informed consent) and enter retrospective data into case report forms on-line. "retrospective data collection" is defined as any data other than patient history collected prior to signing of the informed consent. a set of case report forms (crfs) is provided along with this protocol to track outcomes. the crfs may be completed and retained on site, but the site is recommended to utilize the internet-based data entry system.

Eligibility criteria:
inclusion criteria: * must be a candidate for ablation of barrett's esophagus with the halo ablation system. * must agree to the proposed follow-up schedule and provide informed consent for participation. exclusion criteria: * pregnancy * prior radiation therapy to the esophagus * esophageal varices at risk for bleeding * prior heller myotomy

Keywords: barrett's esophagus dysplasia intestinal metaplasia
improving physical and psychosocial well-being of african american older adults

Conditions: Physical Activity; Psychosocial Stressors

Summary: the proposed research effort will: the purpose of this study is as follows: 1. test the feasibility and acceptability of an eight-week community-based exercise program among aa older adults living in rural areas. 2. determine whether participation in physical exercise through a community-based exercise program in comparison with an attentional control group: a) improves physical well-being b) improves psychosocial well-being

among the aging population, african americans (aa) experience depression and other chronic diseases such as diabetes, hypertension, and cardiovascular disease at a higher rate compared to non-minorities; moreover, those living in rural areas are less likely to seek treatment due to various factors including lack of accessibility, affordability, and acceptability of health care services. fortunately, non-pharmacologic and cost-effective interventions such as physical activity can yield physical, psychosocial, and cognitive benefits for older adults. the purpose of the proposed research effort is to test the feasibility of, and effect of a community-based physical exercise program among community-dwelling older adults living in rural areas on the physical and psychosocial well-being. the research effort will be a randomized controlled trial. fifty african american older adults will be recruited from community centers. a total of 50 participants will be recruited. these adults will be randomly assigned to either the intervention or control group, with each group containing 25 participants. the intervention will occur over a period of eight week. the exercise program will be offered three times a week, with each session lasting one hour. study measures will be collected prior to the start of the exercise program, after the fourth session, after the last session, and at one-month follow-up. the primary outcome measures for the feasibility study will include enrollment rate, randomization rate, retention rate, and data completion rate. additionally, the investigators will examine whether there is improvement i both physical and psychosocial measures. all statistical analyses will be conducted using statistical package for the social sciences (spss) version 22.

Eligibility criteria:
inclusion criteria: 1. at least 65 years of age 2. identifying as aa 3. community dwelling and living in a rural community. 4. sedentary life style (engaging in less than two hours of structured physical exercises whether independently or in a group setting every week) 5. identify as having altered psychosocial health by scoring at least a 10 on the patient health questionnaire (phq-9), which is indicative of moderate depressive symptoms (kroenke, spitzer, \& williams, 2001). exclusion criteria: 1. cognitive impairment as defined by the st. louis university mental status exam

Keywords: physical activity exercise depression anxiety stress
intravenous nitrite infusion for reversal of cerebral vasospasm after subarachnoid hemorrhage

Conditions: Subarachnoid Hemorrhage

Summary: the hypothesis is that intravenous infusion of sodium nitrite is safe and effective for the reversal of cerebral vasospasm after subarachnoid hemorrhage in patients with a cerebral aneurysm.

this is a pilot single center, open-labeled study. patients with subarachnoid hemorrhage admitted to the hospital and who meet entry criteria will be offered enrollment into the study. the patients will be enrolled promptly after detection of the presence of cerebral vasospasm. subjects will receive sodium nitrite infusion. one dose cohort is planned, 64 nmol/min/kg sodium nitrite (0.1325 mg/hour/kg; 0.0442 ml/hour/kg at a concentration of 3mg/ml).

Eligibility criteria:
inclusion criteria: * informed consent obtained from a patient or legal representative before enrollment; * admission to hospital following subarachnoid hemorrhage; * aneurysm confirmed by digital subtraction angiography or ct-angiography after admission; * development of the clinical symptoms and /or signs of cerebral vasospasm and ct-angiography results warranting cerebral angiography. exclusion criteria: * rupture of a fusiform, traumatic, or mycotic aneurysm; * pregnancy (confirmed by a serum human chorionic gonadotropin pregnancy test) or breast feeding; * methemoglobin \> 2% * history of sickle cell disease, thalassemia, or other hemoglobinopathy; * anemia with hemoglobin level less than 6 g/dl; * significant acute or chronic concomitant diseases (including renal, hepatic, cardiovascular, pulmonary, or oncologic disease, sepsis, pulmonary edema, pulmonary embolism) that would be inconsistent with survival for at least 6 months; * history of allergy to nitrites or allergy to other substances that could interfere with nitrite metabolism, within 30 days before screening; * history of red blood cell glucose-6-phosphate dehydrogenase (g6pd)deficiency; * treatment with allopurinol, a medication that could interfere with nitrite metabolism, within 30 days before screening; * other investigational drug within the past 30 days; * other cerebral injury within the past 30 days including previous subarachnoid hemorrhage, stroke, transient ischemic attacks (tia), concussion, head trauma, cranial surgery, radiation therapy to the head.

Keywords: subarachnoid hemorrhage vasospasm nitrite sodium nitrite
a multicenter retrospective review to evaluate the feasibility of dye marking using the ion endoluminal system

Conditions: Lung Cancer

Summary: the overall objective of this study is to assess the ability of the ion endoluminal system to perform pleural based tissue dye marking in anticipation of a lung resection.

this study is a retrospective multicenter chart review of patients who underwent a pleural based tissue dye marking with the ion endoluminal system in anticipation of lung resection. the aim of the study is to assess the feasibility of the ion endoluminal system to perform pleural based tissue marking. as this is a retrospective study, the ion dye marking procedure will have been performed according to the physician's standard technique. all consecutive cases in which a dye marking procedure was attempted and/or completed with the ion endoluminal system will be included.

Eligibility criteria:
inclusion criteria: * subject is 18 years or older at the time of the procedure. * dye marking attempted/performed using the ion endoluminal platform exclusion criteria: * resection not performed following dye marking procedure
a rct to compare performance of two foam dressings on patient well-being related endpoints.

Conditions: Chronic Wounds

Summary: allevyn◊ life and mepilex™ border are both layered foam dressings with a silicone adhesive wound contact layer. both are indicated for the same uses; however allevyn◊ life has a number of attributes designed to meet a range of characteristics associated with principles of wellbeing. the aim for this evaluation is to assess, in a clinical setting and against a number of identified criteria, the performance of the allevyn◊ life dressing compared to mepilex™ border in terms of characteristics of the attributes of wellbeing. ◊ trademark of smith \& nephew ™ all trademarks acknowledged


Eligibility criteria:
inclusion criteria: patients ≥18 years old males and females (females must not be pregnant and must use contraception if of child bearing potential.) presence of a single suitable wound which can be the reference wound without treatment impacting on any other wound(s) on the patient. presence of a suitable wound which can be treated with the available sizes and shapes of allevyn◊ life (10.3cm x 10.3cm, 12.9cm x 12.9cm, 15.4cm x 15.4cm, 21cm x 21cm) and mepilex™ border (7cm x 7.5cm, 10cm x 12.5cm, 15cm x 17.5, 17cm x 20cm) presence of an exuding wound of at least 6 weeks duration at the point of enrolment, healing by secondary intention the patient is able to understand the evaluation and is willing to consent to the evaluation. the patient is available to participate for the anticipated duration of the evaluation. exclusion criteria: patients with confirmed or suspected clinically infected reference wounds. patients with wounds that, in the opinion of the clinician, is likely to heal within a time period of 4 weeks from point of enrolment. patients with a reference wound undergoing treatment with compression therapy. patients where a reference wound cannot be treated in isolation from other wounds. patients with deep reference wounds that, in the opinion of the clinician, necessitate filler material. patients with a known sensitivity to any of the constituents of the evaluation products. patients with a known history of poor compliance with medical treatment. patients who have participated in this evaluation previously and have been withdrawn from the study. patients unable to understand or speak the english language. patients without the capacity to understand and answer wellbeing related questions females who are pregnant or breast feeding.
flor3 gene polymorphism in predicting outcomes of tyrosine kinase inhibitor（tki）stopping in chronic myeloid leukemia

Conditions: Folate; CML; Treatment-free Remission

Summary: for patients with chronic myeloid leukemia in chronic phase (cml-cp) who have achieved a stable deep molecular response (dmr) using bcr-abl1 tyrosine kinase inhibitors (tkis), treatment-free remission (tfr) following tki cessation is an emerging goal. however, about half of the patients relapsed after tki discontinuation. there is no definite examinations to predict the outcome of tki discontinuation. investigators aim to study the relationship between flor3 snp rs139130389 and the outcome of tki discontinuation.

investigators aim to detect folr3 snp rs139130389, and establish its correlation with patients' treatment response, remission time, tki resistance and the outcome of tki stopping.

Eligibility criteria:
inclusion criteria: 1. the patient signs the informed consent form 2. age over 18, male or female 3. the patient was diagnosed as chronic phase of cml. 4. ecog score 0-2 5. receive tki treatment for at least 4 years and continuously obtain mr4 or mr4.5 for at least 3 years. 6. the subjects fully understand and comply with the requirements of the research scheme and are willing to complete the research as planned. exclusion criteria: na

Keywords: folr3 cml tfr
resistance training in type 1 diabetes mellitus

Conditions: Type 1 Diabetes

Summary: the purpose of this study is to learn how different resistance training programs affects blood sugar in young athletes with t1dm.

strength and condition training to improve sport performance has been greatly emphasized over the past 20 years. formal strength and conditioning (s\&c) programming is performed by s\&c coaches who are educated in the field of exercise program with the intentions to bring about particular athletic adaptations through exercise. s\&c programs, previously limited to programs at the college and professional level, are now commonly seen in secondary school athletic programs. with such broad adoption, many athletes that manage chronic diseases, such as type 1 diabetes mellitus, are exposed to elements of these programs. diabetes mellitus impacts more than 10% of the united states population. of these, 5.2% have identified type 1 diabetes mellitus (t1dm) which includes approximately 210,000 individuals under the age of 20. in addition to insulin and dietary management, exercise and physical activity is recommended as an important therapeutic tool for most patients with t1dm. physical activity has been shown to significantly improve glycemic control in individuals with diabetes. additional benefits of exercise include improved cardiovascular fitness, muscle strength, insulin sensitivity and blood glucose control. s\&c programs offer benefits to those living with t1dm as different exercises can be tailored to preserve health. however, there are no exercise prescription or guidelines specifically for adolescent athletes diagnosed with type 1 diabetes participating in strength and conditioning programs. furthermore, there is no available data that states the predictability of glucose response and insulin needs to any of the specific strength and conditioning goals. objective: to assess the impact of different strength and conditioning programming on glycemic control in athletes with t1dm. primary aim: assess glucose response to different resistance training methods. secondary aims: to assess for correlation between lactate and glucose using different resistance training methods.

Eligibility criteria:
inclusion criteria: * ≥ 13 years of age * ≥2 years from date of t1dm diagnosis * prior exposure to strength and conditioning * hba1c ≤ 10% * actively utilizing continuous glucose monitoring for diabetes management exclusion criteria: * physical limitation that may impede ability to complete study procedures * non-english-speaking individual

Keywords: resistance training in type 1 diabetes
a study to evaluate the efficacy and safety of apremilast (cc-10004) in japanese subjects with palmoplantar pustulosis

Conditions: Palmoplantaris Pustulosis

Summary: this study will evaluate whether apremilast is better than placebo (inactive substance in the same form as the drug) for the treatment in japanese subjects with ppp. this study also will evaluate the safety and tolerability of apremilast in japanese subjects with ppp.cc-10004-ppp-001 is a multicenter, randomized, double-blind, placebo-controlled, parallel group, phase 2 study of apremilast in japanese subjects with ppp and inadequate response to treatment with topical steroid and/or topical vitamin d3 derivative preparations. the placebo-controlled period will be 16 weeks and patients will receive apremilast or placebo. after the 16-week placebo-controlled period, all subjects will receive apremilast for 16 weeks. all subjects will have their final study visit 4 weeks after stopping apremilast treatment.


Eligibility criteria:
inclusion criteria: subjects must satisfy the following criteria to be enrolled in the study: 1. subject has a diagnosis of palmoplantar pustulosis with or without pustulotic arthro-osteitis (pao) for at least 24 weeks before screening. 2. subject has a total score of pppasi: ≥ 12 at screening and baseline. 3. subject has moderate or severe pustules/vesicles on palms or soles (pppasi severity score: ≥ 2) at screening and baseline. 4. subject has inadequate response to treatment with topical steroid and/or topical vitamin d3 derivative preparations prior to or at screening. exclusion criteria: the presence of any of the following will exclude a subject from enrollment: 1. subject has a diagnosis of plaque-type psoriasis. 2. subject has the presence of pustular psoriasis in any part of the body other than the palms and soles. 3. subject has obvious improvement during screening (≥ 5 pppasi total score improvement during the screening). 4. subject has received any procedures for focal infection (e.g, tonsillectomy and dental therapy) within 24 weeks of baseline. 5. subject has periodontitis obviously requiring treatment at screening. 6. subject has chronic or recurrent tonsillitis or sinusitis requiring any continuous treatment for a month or more at screening. 7. subject has evidence of skin conditions of hands and feet that would interfere with evaluations of the effect of study medication. 8. subject is pregnant or breastfeeding.

Keywords: palmoplantar pustulosis cc-10004 apremilast only japanese efficacy safety phase 2
injection snoreplasty: comparison between ethanol and ethanolamine oleate

Conditions: Snoring; Apnea

Summary: summary introduction: among various treatments for patients with primary snoring, upper airway resistance syndrome (uars) and obstructive sleep apnea syndrome (osas), the injection snoreplasty arose as a promising alternative in some selected cases. objective: to investigate the efficacy and tolerance of injection snoreplasty comparing ethanol and ethanolamine oleate.


Eligibility criteria:
inclusion criteria: * snoring * rdi \< 15 /h exclusion criteria: * bmi \> 35

Keywords: snoring and mild apnea